Trial Profile

A Phase 2 clinical trial of AST-004

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AST-004 (Primary)
Indications Stroke
Focus Therapeutic Use
Sponsors Astrocyte Pharmaceuticals

Most Recent Events

17 Jun 2025 According to a Astrocyte Pharmaceuticals media release, The company has dosed the first patient in its Phase 2 clinical trial in athletes who suffer concussions during competitive play.
12 Mar 2024 According to a Astrocyte Pharmaceuticals media release, the company is preparing to initiate a Phase 2 clinical trial.
12 Mar 2024 According to a Astrocyte Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for acute ischemic stroke.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com